BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Reports 57% Increase in Fiscal First-Quarter Net Income

Earth Science Tech (OTC: ETST) reported fiscal first-quarter 2027 results highlighted by a 57% year-over-year increase in net income to $715,697 on revenue of $9.0 million, up 3% from the prior-year period. Gross profit rose to $6.3 million, operating cash flow more than doubled to $707,131 and total assets increased to $10.4 million. Diluted earnings per share improved to $0.003 from $0.001, while the company repurchased and retired more than 3.7 million common shares during the quarter without adding debt.

The company said all key operating subsidiaries remained profitable as it continued expanding the licensing footprint of its compounding pharmacy operations across the United States while evaluating opportunities to broaden its telehealth and pharmacy fulfillment platforms. Management will discuss the results and strategic initiatives at its Aug. 31, 2026, annual shareholder meeting, where investors will vote on proposals including the cancellation of the company’s Series B Preferred Stock and hear updates on a potential exchange uplisting aimed at improving liquidity and market visibility.

To view the full press release, visit https://ibn.fm/WHicW

About Earth Science Tech, Inc. (ETST)

Earth Science Tech, Inc. operates as a diversified holding company focused on the health and wellness sector. The Company’s principal operating strategy is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The Company’s healthcare operations are supported by investments in real estate and asset management activities and a consumer products business.

The core of the Company’s value proposition is the seamless integration of patient care, from consultation to fulfillment. This is achieved through the synergy of specialized subsidiaries.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN